Skip to main content
Premium Trial:

Request an Annual Quote

London Genetics, Astrimmune to Develop Biomarkers for Pancreatic Cancer Vaccine

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – London Genetics and Astrimmune today announced a collaboration to identify predictive biomarkers for a pancreatic cancer vaccine being developed by Astrimmune.

The collaboration, being supported with a grant from the UK East Midlands Development Agency, will seek to identify biomarkers predictive of clinical response.

In a statement, the two firms said that Astrimmune's vaccine induces antibody production against gastrin, a hormone which stimulates the growth of many types of gastrointestinal cancer. Different response rates have been observed in clinical trials of gastrin-blocking products, "and there is a clear need for biomarkers to help identify those patients mostly likely to benefit from Astrimmune's product," they said.

Financial and other terms of the deal were not disclosed.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.